These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 11231710)

  • 41. Cost-effectiveness of influenza vaccination of healthy children.
    Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
    Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective.
    Wood SC; Nguyen VH; Schmidt C
    Pharmacoeconomics; 2000 Aug; 18(2):173-83. PubMed ID: 11067651
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients.
    Wongsurakiat P; Lertakyamanee J; Maranetra KN; Jongriratanakul S; Sangkaew S
    J Med Assoc Thai; 2003 Jun; 86(6):497-508. PubMed ID: 12924797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost effectiveness analysis of elementary school-located vaccination against influenza--results from a randomized controlled trial.
    Yoo BK; Humiston SG; Szilagyi PG; Schaffer SJ; Long C; Kolasa M
    Vaccine; 2013 Apr; 31(17):2156-64. PubMed ID: 23499607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
    Chit A; Becker DL; DiazGranados CA; Maschio M; Yau E; Drummond M
    Lancet Infect Dis; 2015 Dec; 15(12):1459-66. PubMed ID: 26362172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of influenza vaccination in high-risk children in Argentina.
    Dayan GH; Nguyen VH; Debbag R; Gómez R; Wood SC
    Vaccine; 2001 Jul; 19(30):4204-13. PubMed ID: 11457546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years.
    Nichol KL; Goodman M
    Pharmacoeconomics; 1999; 16 Suppl 1():63-71. PubMed ID: 10623378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Economic evaluation of vaccination against influenza in New Zealand.
    Scott WG; Scott HM
    Pharmacoeconomics; 1996 Jan; 9(1):51-60. PubMed ID: 10160087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Worksite influenza immunization programs. Insight into the implementation and cost-benefit.
    Olsen GW; Steinberg ME; Ley CA
    AAOHN J; 2005 Mar; 53(3):105-10. PubMed ID: 15789965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Anti-influenza vaccination for active persons (25-64 years): a cost-benefit study].
    Levy E; Levy P
    Rev Epidemiol Sante Publique; 1992; 40(5):285-95. PubMed ID: 1480805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.
    Wateska AR; Nowalk MP; Zimmerman RK; Smith KJ; Lin CJ
    BMC Infect Dis; 2018 Jan; 18(1):52. PubMed ID: 29370768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling.
    Dawa J; Emukule GO; Barasa E; Widdowson MA; Anzala O; van Leeuwen E; Baguelin M; Chaves SS; Eggo RM
    BMC Med; 2020 Aug; 18(1):223. PubMed ID: 32814581
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women.
    Skedgel C; Langley JM; MacDonald NE; Scott J; McNeil S
    Can J Public Health; 2011; 102(6):445-50. PubMed ID: 22164556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine.
    Shim E; Brown ST; DePasse J; Nowalk MP; Raviotta JM; Smith KJ; Zimmerman RK
    Am J Prev Med; 2016 Sep; 51(3):309-17. PubMed ID: 27079638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
    García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
    Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The comparative value of various employer-sponsored influenza vaccination clinics.
    Zimmerman RK; Wiringa AE; Nowalk MP; Lin CJ; Rousculp MD; Mitgang EA; Lee BY
    J Occup Environ Med; 2012 Sep; 54(9):1107-17. PubMed ID: 22929797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
    Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
    Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Influenza vaccination in the elderly population in Mexico: economic considerations].
    Gutiérrez JP; Bertozzi SM
    Salud Publica Mex; 2005; 47(3):234-9. PubMed ID: 16104466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.
    Talbird SE; Brogan AJ; Winiarski AP; Sander B
    Am J Health Syst Pharm; 2009 Mar; 66(5):469-80. PubMed ID: 19233995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.